0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peptide-based Drug Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-30R5170
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Peptide based Drug Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Peptide-based Drug Market Research Report 2025

Code: QYRE-Auto-30R5170
Report
July 2025
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Peptide-based Drug Market Size

The global market for Peptide-based Drug was valued at US$ 40090 million in the year 2024 and is projected to reach a revised size of US$ 72680 million by 2031, growing at a CAGR of 9.0% during the forecast period.

Peptide-based Drug Market

Peptide-based Drug Market

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
This report aims to provide a comprehensive presentation of the global market for Peptide-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-based Drug.
The Peptide-based Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide-based Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-based Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Peptide-based Drug Market Report

Report Metric Details
Report Name Peptide-based Drug Market
Accounted market size in year US$ 40090 million
Forecasted market size in 2031 US$ 72680 million
CAGR 9.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, Merck, The Medicines, J & J
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Peptide-based Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Peptide-based Drug Market growing?

Ans: The Peptide-based Drug Market witnessing a CAGR of 9.0% during the forecast period 2025-2031.

What is the Peptide-based Drug Market size in 2031?

Ans: The Peptide-based Drug Market size in 2031 will be US$ 72680 million.

Who are the main players in the Peptide-based Drug Market report?

Ans: The main players in the Peptide-based Drug Market are Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, Merck, The Medicines, J & J

What are the Application segmentation covered in the Peptide-based Drug Market report?

Ans: The Applications covered in the Peptide-based Drug Market report are Cancer, Metabolic Disorders, Central Nervous System, Other

What are the Type segmentation covered in the Peptide-based Drug Market report?

Ans: The Types covered in the Peptide-based Drug Market report are Injection, Oral, Other

Recommended Reports

Peptide Therapeutics

Amino Acids & Synthesis

Related Drug Markets

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-based Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peptide-based Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-based Drug Market Perspective (2020-2031)
2.2 Global Peptide-based Drug Growth Trends by Region
2.2.1 Global Peptide-based Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide-based Drug Historic Market Size by Region (2020-2025)
2.2.3 Peptide-based Drug Forecasted Market Size by Region (2026-2031)
2.3 Peptide-based Drug Market Dynamics
2.3.1 Peptide-based Drug Industry Trends
2.3.2 Peptide-based Drug Market Drivers
2.3.3 Peptide-based Drug Market Challenges
2.3.4 Peptide-based Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-based Drug Players by Revenue
3.1.1 Global Top Peptide-based Drug Players by Revenue (2020-2025)
3.1.2 Global Peptide-based Drug Revenue Market Share by Players (2020-2025)
3.2 Global Peptide-based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide-based Drug Revenue
3.4 Global Peptide-based Drug Market Concentration Ratio
3.4.1 Global Peptide-based Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-based Drug Revenue in 2024
3.5 Global Key Players of Peptide-based Drug Head office and Area Served
3.6 Global Key Players of Peptide-based Drug, Product and Application
3.7 Global Key Players of Peptide-based Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-based Drug Breakdown Data by Type
4.1 Global Peptide-based Drug Historic Market Size by Type (2020-2025)
4.2 Global Peptide-based Drug Forecasted Market Size by Type (2026-2031)
5 Peptide-based Drug Breakdown Data by Application
5.1 Global Peptide-based Drug Historic Market Size by Application (2020-2025)
5.2 Global Peptide-based Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide-based Drug Market Size (2020-2031)
6.2 North America Peptide-based Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide-based Drug Market Size by Country (2020-2025)
6.4 North America Peptide-based Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide-based Drug Market Size (2020-2031)
7.2 Europe Peptide-based Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide-based Drug Market Size by Country (2020-2025)
7.4 Europe Peptide-based Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-based Drug Market Size (2020-2031)
8.2 Asia-Pacific Peptide-based Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide-based Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide-based Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide-based Drug Market Size (2020-2031)
9.2 Latin America Peptide-based Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide-based Drug Market Size by Country (2020-2025)
9.4 Latin America Peptide-based Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-based Drug Market Size (2020-2031)
10.2 Middle East & Africa Peptide-based Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide-based Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide-based Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide-based Drug Introduction
11.1.4 Sanofi Revenue in Peptide-based Drug Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Peptide-based Drug Introduction
11.2.4 Teva Revenue in Peptide-based Drug Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide-based Drug Introduction
11.3.4 Novo Nordisk Revenue in Peptide-based Drug Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide-based Drug Introduction
11.4.4 Takeda Revenue in Peptide-based Drug Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide-based Drug Introduction
11.5.4 Eli Lilly Revenue in Peptide-based Drug Business (2020-2025)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide-based Drug Introduction
11.6.4 AstraZeneca Revenue in Peptide-based Drug Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide-based Drug Introduction
11.7.4 Novartis Revenue in Peptide-based Drug Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide-based Drug Introduction
11.8.4 AbbVie Revenue in Peptide-based Drug Business (2020-2025)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Details
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide-based Drug Introduction
11.9.4 Ipsen Revenue in Peptide-based Drug Business (2020-2025)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide-based Drug Introduction
11.10.4 Ferring Revenue in Peptide-based Drug Business (2020-2025)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Peptide-based Drug Introduction
11.11.4 Merck Revenue in Peptide-based Drug Business (2020-2025)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Details
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide-based Drug Introduction
11.12.4 The Medicines Revenue in Peptide-based Drug Business (2020-2025)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Details
11.13.2 J & J Business Overview
11.13.3 J & J Peptide-based Drug Introduction
11.13.4 J & J Revenue in Peptide-based Drug Business (2020-2025)
11.13.5 J & J Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Peptide-based Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Injection
 Table 3. Key Players of Oral
 Table 4. Key Players of Other
 Table 5. Global Peptide-based Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Peptide-based Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Peptide-based Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Peptide-based Drug Market Share by Region (2020-2025)
 Table 9. Global Peptide-based Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Peptide-based Drug Market Share by Region (2026-2031)
 Table 11. Peptide-based Drug Market Trends
 Table 12. Peptide-based Drug Market Drivers
 Table 13. Peptide-based Drug Market Challenges
 Table 14. Peptide-based Drug Market Restraints
 Table 15. Global Peptide-based Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Peptide-based Drug Market Share by Players (2020-2025)
 Table 17. Global Top Peptide-based Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-based Drug as of 2024)
 Table 18. Ranking of Global Top Peptide-based Drug Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Peptide-based Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Peptide-based Drug, Headquarters and Area Served
 Table 21. Global Key Players of Peptide-based Drug, Product and Application
 Table 22. Global Key Players of Peptide-based Drug, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Peptide-based Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Peptide-based Drug Revenue Market Share by Type (2020-2025)
 Table 26. Global Peptide-based Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Peptide-based Drug Revenue Market Share by Type (2026-2031)
 Table 28. Global Peptide-based Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Peptide-based Drug Revenue Market Share by Application (2020-2025)
 Table 30. Global Peptide-based Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Peptide-based Drug Revenue Market Share by Application (2026-2031)
 Table 32. North America Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Peptide-based Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Peptide-based Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Peptide-based Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Peptide-based Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Peptide-based Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Peptide-based Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Peptide-based Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Peptide-based Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Peptide-based Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Peptide-based Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Peptide-based Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Sanofi Company Details
 Table 48. Sanofi Business Overview
 Table 49. Sanofi Peptide-based Drug Product
 Table 50. Sanofi Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 51. Sanofi Recent Development
 Table 52. Teva Company Details
 Table 53. Teva Business Overview
 Table 54. Teva Peptide-based Drug Product
 Table 55. Teva Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 56. Teva Recent Development
 Table 57. Novo Nordisk Company Details
 Table 58. Novo Nordisk Business Overview
 Table 59. Novo Nordisk Peptide-based Drug Product
 Table 60. Novo Nordisk Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 61. Novo Nordisk Recent Development
 Table 62. Takeda Company Details
 Table 63. Takeda Business Overview
 Table 64. Takeda Peptide-based Drug Product
 Table 65. Takeda Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 66. Takeda Recent Development
 Table 67. Eli Lilly Company Details
 Table 68. Eli Lilly Business Overview
 Table 69. Eli Lilly Peptide-based Drug Product
 Table 70. Eli Lilly Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 71. Eli Lilly Recent Development
 Table 72. AstraZeneca Company Details
 Table 73. AstraZeneca Business Overview
 Table 74. AstraZeneca Peptide-based Drug Product
 Table 75. AstraZeneca Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 76. AstraZeneca Recent Development
 Table 77. Novartis Company Details
 Table 78. Novartis Business Overview
 Table 79. Novartis Peptide-based Drug Product
 Table 80. Novartis Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 81. Novartis Recent Development
 Table 82. AbbVie Company Details
 Table 83. AbbVie Business Overview
 Table 84. AbbVie Peptide-based Drug Product
 Table 85. AbbVie Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 86. AbbVie Recent Development
 Table 87. Ipsen Company Details
 Table 88. Ipsen Business Overview
 Table 89. Ipsen Peptide-based Drug Product
 Table 90. Ipsen Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 91. Ipsen Recent Development
 Table 92. Ferring Company Details
 Table 93. Ferring Business Overview
 Table 94. Ferring Peptide-based Drug Product
 Table 95. Ferring Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 96. Ferring Recent Development
 Table 97. Merck Company Details
 Table 98. Merck Business Overview
 Table 99. Merck Peptide-based Drug Product
 Table 100. Merck Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 101. Merck Recent Development
 Table 102. The Medicines Company Details
 Table 103. The Medicines Business Overview
 Table 104. The Medicines Peptide-based Drug Product
 Table 105. The Medicines Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 106. The Medicines Recent Development
 Table 107. J & J Company Details
 Table 108. J & J Business Overview
 Table 109. J & J Peptide-based Drug Product
 Table 110. J & J Revenue in Peptide-based Drug Business (2020-2025) & (US$ Million)
 Table 111. J & J Recent Development
 Table 112. Research Programs/Design for This Report
 Table 113. Key Data Information from Secondary Sources
 Table 114. Key Data Information from Primary Sources
 Table 115. Authors List of This Report


List of Figures
 Figure 1. Peptide-based Drug Picture
 Figure 2. Global Peptide-based Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Peptide-based Drug Market Share by Type: 2024 VS 2031
 Figure 4. Injection Features
 Figure 5. Oral Features
 Figure 6. Other Features
 Figure 7. Global Peptide-based Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Peptide-based Drug Market Share by Application: 2024 VS 2031
 Figure 9. Cancer Case Studies
 Figure 10. Metabolic Disorders Case Studies
 Figure 11. Central Nervous System Case Studies
 Figure 12. Other Case Studies
 Figure 13. Peptide-based Drug Report Years Considered
 Figure 14. Global Peptide-based Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Peptide-based Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Peptide-based Drug Market Share by Region: 2024 VS 2031
 Figure 17. Global Peptide-based Drug Market Share by Players in 2024
 Figure 18. Global Top Peptide-based Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-based Drug as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Peptide-based Drug Revenue in 2024
 Figure 20. North America Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Peptide-based Drug Market Share by Country (2020-2031)
 Figure 22. United States Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Peptide-based Drug Market Share by Country (2020-2031)
 Figure 26. Germany Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Peptide-based Drug Market Share by Region (2020-2031)
 Figure 34. China Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Peptide-based Drug Market Share by Country (2020-2031)
 Figure 42. Mexico Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Peptide-based Drug Market Share by Country (2020-2031)
 Figure 46. Turkey Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Peptide-based Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Sanofi Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 50. Teva Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 51. Novo Nordisk Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 52. Takeda Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 53. Eli Lilly Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 54. AstraZeneca Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 55. Novartis Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 56. AbbVie Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 57. Ipsen Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 58. Ferring Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 59. Merck Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 60. The Medicines Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 61. J & J Revenue Growth Rate in Peptide-based Drug Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD